{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:57Z","timestamp":1763017857244},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jns.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T17:53:36Z","timestamp":1517853216000},"page":"48-54","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia"],"prefix":"10.1016","volume":"389","author":[{"given":"Chih-Chun","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.02.014_bb0005","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0015","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.014_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jns.2018.02.014_bb0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/1098-2396(20010101)39:1<51::AID-SYN7>3.0.CO;2-Z","article-title":"Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats","volume":"39","author":"Grimm","year":"2001","journal-title":"Synapse"},{"key":"10.1016\/j.jns.2018.02.014_bb0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1073858402239588","article-title":"Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems","volume":"9","author":"Zhou","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2018.02.014_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E","volume":"570","author":"Cadet","year":"1989","journal-title":"Ann. N. Y. Acad Sci."},{"key":"10.1016\/j.jns.2018.02.014_bb0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0149-7634(94)90001-9","article-title":"Free radical mechanisms in schizophrenia and tardive dyskinesia","volume":"18","author":"Cadet","year":"1994","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jns.2018.02.014_bb0045","first-page":"1207","article-title":"Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia","author":"Flood","year":"1998","journal-title":"Psychiatry Interpers. Biol. Process."},{"key":"10.1016\/j.jns.2018.02.014_bb0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","article-title":"Antiviral activity of 1-adamantanamine (Amantadine)","volume":"144","author":"Davies","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.jns.2018.02.014_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/009127007101100308","article-title":"The antiparkinson properties of amantadine in drug-induced Parkinsonism","volume":"11","author":"Kelly","year":"1971","journal-title":"J. Clin. Pharmacol. New Drugs"},{"key":"10.1016\/j.jns.2018.02.014_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.2042-7158.1974.tb09272.x","article-title":"Effect of several dopaminergic drugs and trihexyphenidyl on cholinergic parameters in the rat striatum","volume":"26","author":"Consolo","year":"1974","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","article-title":"Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study","volume":"206","author":"Kornhuber","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM197103252841216","article-title":"Amantadine for dyskinesia tarda","volume":"284","author":"Vale","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJM197110072851516","article-title":"Amantadine hydrochloride treatment of tardive dyskinesia","volume":"285","author":"Decker","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0080","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJM197204062861424","article-title":"Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism","volume":"286","author":"Janowsky","year":"1972","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0085","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archpsyc.1976.01770050055008","article-title":"A controlled trial of amantadine in drug-induced extrapyramidal disorders","volume":"33","author":"DiMascio","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0090","first-page":"167","article-title":"No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind cross-over, placebo-controlled study in medicated chronic schizophrenic patients","volume":"56","author":"Silver","year":"1995","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.014_bb0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0006-8993(73)90037-1","article-title":"On the source of GABA-containing terminals in the substantia nigra. Electron microscopic autoradiographic and biochemical studies","volume":"54","author":"Hattori","year":"1973","journal-title":"Brain Res."},{"key":"10.1016\/j.jns.2018.02.014_bb0115","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1146\/annurev.ne.17.030194.003033","article-title":"GABAA receptor channels","volume":"17","author":"Macdonald","year":"1994","journal-title":"Ann. Rev. Neurosci."},{"key":"10.1016\/j.jns.2018.02.014_bb0120","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.bjp.0706796","article-title":"Mechanism of action of benzodiazepines on GABAA receptors","volume":"148","author":"Campo-Soria","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/290149a0","article-title":"3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain","volume":"290","author":"Hill","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.jns.2018.02.014_bb0130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0163-7258(95)00016-A","article-title":"GABAB receptors","volume":"67","author":"Kerr","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jns.2018.02.014_bb0135","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)03031-X","article-title":"The Maryland Psychiatric Research Center scale and the characterization of involuntary movements","volume":"70","author":"Cassady","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jns.2018.02.014_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00005053-196207000-00009","article-title":"Chronic involuntary movements induced by phenothiazines","volume":"135","author":"Druckman","year":"1962","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.014_bb0150","first-page":"729","article-title":"Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model","volume":"17","author":"Singh","year":"1982","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0361-9230(83)90188-0","article-title":"Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement","volume":"11","author":"Singh","year":"1983","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.jns.2018.02.014_bb0160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/106002808301700705","article-title":"Diazepam in tardive dyskinesia","volume":"17","author":"Weber","year":"1983","journal-title":"Drug Intell. Clin. Pharm."},{"key":"10.1016\/j.jns.2018.02.014_bb0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-198804000-00028","article-title":"The effect of benzodiazepines on tardive dyskinesia symptoms","volume":"8","author":"Csernansky","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0170","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1176\/ajp.135.12.1562","article-title":"Baclofen in the treatment of tardive dyskinesia","volume":"135","author":"Vasavan Nair","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00431840","article-title":"Effect of baclofen on tardive dyskinesia","volume":"56","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.014_bb0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002826-198212000-00004","article-title":"Baclofen in tardive dyskinesia patients maintained on neuroleptics","volume":"5","author":"Stewart","year":"1982","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0185","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00432517","article-title":"The treatment of tardive dyskinesia with baclofen","volume":"87","author":"Glazer","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.014_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJM197507172930317","article-title":"Choline for tardive dyskinesia","volume":"293","author":"Davis","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0195","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.v62n1004","article-title":"Treatment of tardive dyskinesia with donepezil: a pilot study","volume":"62","author":"Caroff","year":"2001","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.jns.2018.02.014_bb0200","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00492207","article-title":"Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study","volume":"65","author":"De Montigny","year":"1979","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jns.2018.02.014_bb0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3109\/00048678109159413","article-title":"Double blind controlled trial of deanol in tardive dyskinesia","volume":"15","author":"George","year":"1981","journal-title":"Aust. New Zeal. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0210","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0024-3205(76)90095-3","article-title":"Choline in tardive dyskinesia and Huntington's disease","volume":"19","author":"Davis","year":"1976","journal-title":"Life Sci."},{"key":"10.1016\/j.jns.2018.02.014_bb0215","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1176\/ajp.136.11.1458","article-title":"Treatment of tardive dyskinesia with lecithin","volume":"136","author":"Jackson","year":"1979","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0220","first-page":"149","article-title":"A cross-over study of lecithin treatment of tardive dyskinesia","volume":"51","author":"Gelenberg","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0225","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-3223(86)90142-3","article-title":"Meclofenoxate therapy in tardive dyskinesia: a preliminary report","volume":"21","author":"Izumi","year":"1986","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0230","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.140.12.1629","article-title":"The use of tacrine for tardive dyskinesia","volume":"140","author":"Ingram","year":"1983","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2018.02.014_bb0235","first-page":"CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2018.02.014_bb0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.pnpbp.2004.05.045","article-title":"Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials","volume":"28","author":"Tammenmaa","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0245","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled cross-over trial","volume":"68","author":"Caroff","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2016.06.003","article-title":"Ginkgo biloba and vitamin E ameliorate haloperidol-induced vacuous chewingmovement and brain-derived neurotrophic factor expression in a rat tardive dyskinesia model","volume":"148","author":"Shi","year":"2016","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jns.2018.02.014_bb0255","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.phymed.2016.10.009","article-title":"Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation","volume":"23","author":"An","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jns.2018.02.014_bb0260","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev.nu.04.070184.002323","article-title":"Vitamin B6 metabolism","volume":"4","author":"Ink","year":"1984","journal-title":"Ann. Rev. Nutr."},{"key":"10.1016\/j.jns.2018.02.014_bb0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1570-9639(03)00076-1","article-title":"Antitumor effect of vitamin B6 and its mechanisms","volume":"1647","author":"Komatsu","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2018.02.014_bb0270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.freeradbiomed.2003.09.012","article-title":"Effect of vitamin B 6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2 -treated U937 monocytes","volume":"36","author":"Kannan","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0275","first-page":"241","article-title":"Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study","volume":"22","author":"Lerner","year":"1999","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0280","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.schres.2005.03.008","article-title":"Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia","volume":"77","author":"Gharabawi","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jns.2018.02.014_bb0285","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1176\/appi.ajp.158.9.1511","article-title":"Vitamin B 6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, cross-over study","volume":"158","author":"Lerner","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0290","first-page":"25","article-title":"Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, cross-over study","author":"Lerner","year":"2007","journal-title":"Psychiatry Interpers. Biol. Process."},{"key":"10.1016\/j.jns.2018.02.014_bb0295","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM198308253090801","article-title":"Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome","volume":"309","author":"Schaumburg","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0300","first-page":"219","article-title":"Elevated B6 levels and peripheral neuropathies","volume":"48","author":"Scott","year":"2008","journal-title":"Electromyogr. Clin. Neurophysiol."},{"key":"10.1016\/j.jns.2018.02.014_bb0305","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(87)92878-9","article-title":"Alpha-tocopherol in tardive dyskinesia","volume":"1","author":"Lohr","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.02.014_bb0310","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0315","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0320","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0325","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0330","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","article-title":"Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study","volume":"149","author":"Shriqui","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.014_bb0340","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group","volume":"56","author":"Adler","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2018.02.014_bb0345","first-page":"CD000209","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2018.02.014_bb0350","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/423821a","article-title":"The missing link in Ginkgo evolution","volume":"423","author":"Zhou","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jns.2018.02.014_bb0355","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0360","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(95)91382-3","article-title":"Improvement of sleep quality in elderly people by controlled-release melatonin","volume":"346","author":"Garfinkel","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.02.014_bb0365","doi-asserted-by":"crossref","first-page":"PL271","DOI":"10.1016\/0024-3205(94)00666-0","article-title":"Melatonin: a peroxyl radical scavenger more effective than vitamin E","volume":"55","author":"Pieri","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.jns.2018.02.014_bb0370","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4088\/JCP.v61n0803","article-title":"Is melatonin treatment effective for tardive dyskinesia?","volume":"61","author":"Shamir","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0375","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archpsyc.58.11.1049","article-title":"Melatonin treatment for tardive dyskinesia","volume":"58","author":"Shamir","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0380","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1254\/jphs.11079SC","article-title":"Yokukansan enhances pentobarbital-induced sleep in socially isolated mice: possible involvement of GABA(A)-benzodiazepine receptor complex","volume":"116","author":"Egashira","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.jns.2018.02.014_bb0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jep.2015.02.046","article-title":"Yokukansan, a traditional Japanese medicine, decreases head-twitch behaviors and serotonin 2A receptors in the prefrontal cortex of isolation-stressed mice","volume":"166","author":"Ueki","year":"2015","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0390","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1211\/0022357991772853","article-title":"Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats","volume":"51","author":"Shimada","year":"1999","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0395","first-page":"438","article-title":"YGS40, an active fraction of yi-gan san, reduces hydrogen peroxide-induced apoptosis in PC12 cells","volume":"13","author":"Zhao","year":"2015","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.jns.2018.02.014_bb0400","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.pnpbp.2007.12.003","article-title":"Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study","volume":"32","author":"Miyaoka","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Bio Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0405","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0410","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","article-title":"Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study","volume":"62","author":"Durif","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.014_bb0415","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajp.2013.12.016","article-title":"Management of tardive syndromes with clozapine: a case series","volume":"8","author":"Grover","year":"2014","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jns.2018.02.014_bb0420","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2018.02.014_bb0425","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1523\/JNEUROSCI.2699-05.2006","article-title":"Synaptic vesicle protein 2 enhances release probability at quiescent synapses","volume":"26","author":"Custer","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2018.02.014_bb0430","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1523\/JNEUROSCI.4521-08.2009","article-title":"SV2 renders primed synaptic vesicles competent for Ca2+\u2212induced exocytosis","volume":"29","author":"Chang","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2018.02.014_bb0435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.WNL.0000073538.60021.50","article-title":"Levetiracetam as a treatment for tardive dyskinesia: a case report","volume":"61","author":"McGavin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.014_bb0440","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.jcp.0000203823.60603.80","article-title":"Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: a case series","volume":"26","author":"Bona","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0445","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mds.20835","article-title":"Levetiracetam in tardive dyskinesia: an open label study","volume":"21","author":"Konitsiotis","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.014_bb0450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.WNF.0000228807.49044.7D","article-title":"Levetiracetam in tardive dyskinesia","volume":"29","author":"Meco","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0455","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v69n0405","article-title":"Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Woods","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0460","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF03000311","article-title":"The \u201cnootropic\u201d approach to the pharmacology of the integrative activity of the brain","volume":"8","author":"Giurgea","year":"1973","journal-title":"Cond. Reflex."},{"key":"10.1016\/j.jns.2018.02.014_bb0465","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/0006-2952(76)90004-6","article-title":"Effect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism. Comparison with naftidrofuryl and methamphetamine","volume":"25","author":"Nickolson","year":"1976","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0470","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0306-3623(87)90252-7","article-title":"Effect of piracetam on electrocorticogram and local cerebral glucose utilization in the rat","volume":"18","author":"Grau","year":"1987","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0475","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00735884","article-title":"Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice","volume":"94","author":"Pilch","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.014_bb0480","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0197-4580(92)90006-J","article-title":"Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment","volume":"13","author":"Stoll","year":"1992","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2018.02.014_bb0485","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1157.1988.tb03740.x","article-title":"Effect of antiepileptic and antimyoclonic drugs on serotonin receptors in vitro","volume":"29","author":"Pranzatelli","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2018.02.014_bb0490","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01243753","article-title":"The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons","volume":"55","author":"Olpe","year":"1982","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2018.02.014_bb0495","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0741-8329(95)02050-0","article-title":"Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol","volume":"13","author":"Brand\u00e3o","year":"1996","journal-title":"Alcohol"},{"key":"10.1016\/j.jns.2018.02.014_bb0500","first-page":"255","article-title":"Piracetam for drug-induced dyskinesia","volume":"48","author":"Chaturvedi","year":"1987","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0505","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004714-200104000-00026","article-title":"Piracetam in the treatment of tardive dyskinesia and akathisia: a case report","volume":"21","author":"Fehr","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0510","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4088\/JCP.v68n0709","article-title":"Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled cross-over study","volume":"68","author":"Libov","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0515","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002130050958","article-title":"Phenylalanine kinetics are associated with tardive dyskinesia in men but not in women","volume":"143","author":"Richardson","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.014_bb0520","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1748-1716.1992.tb09422.x","article-title":"Effect of branched-chain amino acid supplementation on the exercise-induced change in aromatic amino acid concentration in human muscle","volume":"146","author":"Blomstrand","year":"1992","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.jns.2018.02.014_bb0525","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s002130050959","article-title":"Branched chain amino acids decrease tardive dyskinesia symptoms","volume":"143","author":"Richardson","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.014_bb0530","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v65n0116","article-title":"Branched chain amino acid treatment of tardive dyskinesia in children and adolescents","volume":"65","author":"Richardson","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0535","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1176\/appi.ajp.160.6.1117","article-title":"Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men","volume":"160","author":"Richardson","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0540","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.parkreldis.2016.09.004","article-title":"Propranolol therapy for tardive dyskinesia: a retrospective examination","volume":"32","author":"Hatcher-Martin","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2018.02.014_bb0545","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jns.2018.02.014_bb0550","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/mds.20904","article-title":"Botulinum toxin as a treatment for tardive dyskinesia","volume":"21","author":"van Harten","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.014_bb0555","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.pnpbp.2007.09.010","article-title":"Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature","volume":"32","author":"Hennings","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0560","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e31818ddbc4","article-title":"Botulinum toxin in painful tardive dyskinesia","volume":"32","author":"Tschopp","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0565","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/JCP.0b013e31820f4f70","article-title":"Treatment of intractable tardive lingual dyskinesia with botulinum toxin","volume":"31","author":"Beckmann","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0570","first-page":"438","article-title":"Botulinum toxin in treatment of tardive dyskinetic syndrome","volume":"10","author":"Truong","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0575","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00004714-199712000-00016","article-title":"Botulinum toxin in the treatment of tardive dystonia","volume":"17","author":"Chatterjee","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0580","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.parkreldis.2010.04.007","article-title":"Lingual protrusion dystonia: frequency, etiology and botulinum toxin therapy","volume":"16","author":"Esper","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2018.02.014_bb0585","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-199702000-00012","article-title":"An open-label study of botulinum toxin A for treatment of tardive dystonia","volume":"20","author":"Tarsy","year":"1997","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.014_bb0590","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X","article-title":"Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia","volume":"15","author":"Rapaport","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.014_bb0595","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.pnpbp.2007.10.004","article-title":"Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study","volume":"32","author":"Slotema","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0600","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1176\/ajp.135.8.991","article-title":"The effects of electroconvulsive therapy on tardive dyskinesia","volume":"135","author":"Price","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0605","first-page":"265","article-title":"ECT and tardive dyskinesia: two cases and a review","volume":"44","author":"Chacko","year":"1983","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0610","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00005053-198403000-00007","article-title":"Tardive dystonia, catatonia, and electroconvulsive therapy","volume":"172","author":"Kwentus","year":"1984","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.014_bb0615","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00005053-198802000-00009","article-title":"Improvement of tardive dyskinesia associated with electroconvulsive therapy","volume":"176","author":"Gosek","year":"1988","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.014_bb0620","first-page":"328","article-title":"Tardive dyskinesia and electroconvulsive therapy","volume":"4","author":"Malek-Ahmadi","year":"1988","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.jns.2018.02.014_bb0625","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/089198879000300209","article-title":"ECT and tardive dyskinesia","volume":"3","author":"Hay","year":"1990","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"10.1016\/j.jns.2018.02.014_bb0630","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1192\/bjp.159.3.446a","article-title":"Tardive dyskinesia, depression and ECT","volume":"159","author":"Besson","year":"1991","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0635","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00124509-200412000-00014","article-title":"Successful electroconvulsive treatment of depression associated with a marked reduction in the symptoms of tardive dyskinesia","volume":"20","author":"Nobuhara","year":"2004","journal-title":"J. ECT"},{"key":"10.1016\/j.jns.2018.02.014_bb0640","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.yct.0000167464.79327.0d","article-title":"Remission of tardive dystonia (blepharospasm) after electroconvulsive therapy in a patient with treatment-refractory schizophrenia","volume":"21","author":"Sienaert","year":"2005","journal-title":"J. ECT"},{"key":"10.1016\/j.jns.2018.02.014_bb0645","doi-asserted-by":"crossref","DOI":"10.1097\/YCT.0b013e31829e0aea","article-title":"Electroconvulsive therapy for a patient with persistent tardive dyskinesia","volume":"29","author":"Peng","year":"2013","journal-title":"J. ECT"},{"key":"10.1016\/j.jns.2018.02.014_bb0650","first-page":"865","article-title":"Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems","volume":"18","author":"Holcomb","year":"1983","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0655","first-page":"92","article-title":"Electroconvulsive therapy in a patient with mania, parkinsonism, and tardive dyskinesia","volume":"4","author":"Roth","year":"1988","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.jns.2018.02.014_bb0660","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1176\/ajp.135.10.1235","article-title":"A single-blind study of ECT in patients with tardive dyskinesia","volume":"135","author":"Asnis","year":"1978","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.014_bb0665","first-page":"194","article-title":"The effect of electroconvulsive therapy on tardive dyskinesia: a prospective study","volume":"6","author":"Yassa","year":"1990","journal-title":"Convuls. Ther."},{"key":"10.1016\/j.jns.2018.02.014_bb0670","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/NDT.S62490","article-title":"The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study","volume":"10","author":"Yasui-Furukori","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T21:29:23Z","timestamp":1693517363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":134,"alternative-id":["S0022510X18300728"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.014","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}